DiaGenic, a Norwegian molecular diagnostics company, is validating two tests — one for early-stage breast cancer diagnosis, the other for early-stage Alzheimer’s detection — and plans to have prototypes for both ready by the end of this year, according to a company official.
 
The prototypes have been developed for both tests using Applied Biosystems’ RT-PCR TaqMan platform as well as custom CodeLink microarrays from GE Healthcare.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.